General Information of Drug (ID: DMZ6VD5)

Drug Name
M-518101 Drug Info
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Phase 3 [1]
Psoriasis vulgaris EA90 Phase 3 [2]
Cross-matching ID
PubChem CID
16122802
TTD Drug ID
DMZ6VD5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Phosphodiesterase (PDE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NM-702 DMDJLY9 Angina pectoris BA40 Phase 3 [3]
Piroximone DMQXJDM Cardiac failure BD10-BD13 Discontinued in Phase 3 [4]
AA-2379 DM78623 Inflammation 1A00-CA43.1 Discontinued in Phase 2 [5]
HN-10200 DMYJ1ZB Cardiac failure BD10-BD13 Discontinued in Phase 2 [6]
TIBENELAST DMYH2PU Asthma CA23 Discontinued in Phase 2 [7]
ALBIFYLLINE DMVBKLO Sepsis 1G40-1G41 Discontinued in Phase 1 [8]
Sch-45752 DME9Q3V Asthma CA23 Terminated [9]
Isomazole DM4YJ2W Asthma CA23 Terminated [10]
BBB-022 DMITV4F Cerebrovascular ischaemia 8B1Z Terminated [11]
JTT-608 DMZBNHC Diabetic complication 5A2Y Terminated [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase (PDE) TTUST1O NOUNIPROTAC Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01989429) Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients. U.S. National Institutes of Health.
3 The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
4 Circulatory effects of the PDE-inhibitors piroximone and enoximone. Br J Clin Pharmacol. 1993 Oct;36(4):309-14.
5 Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action. Agents Actions. 1989 Nov;28(3-4):248-55.
6 HN-10200 causes endothelium-independent relaxations in isolated canine arteries. Cardiovasc Drugs Ther. 1992 Apr;6(2):159-65.
7 Effect of tibenelast (a phosphodiesterase inhibitor) and theophylline on isoproterenol-stimulated heart rate, cyclic AMP and norepinephrine levels. Pharmacology. 1993;46(3):142-7.
8 Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 1995 Jan;25(1):147-53.
9 SCH 45752--an inhibitor of calmodulin-sensitive cyclic nucleotide phosphodiesterase activity. J Antibiot (Tokyo). 1993 Feb;46(2):207-13.
10 Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol. 1991 Sep;18(3):386-97.
11 Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001 Dec;21(12):1393-400.
12 JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur J Pharmacol. 1999 Feb 12;367(1):91-9.